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The standard method for the detection of botulinum neurotoxin is currently the mouse bioassay which is
considered to be the most reliable method for the detection of the active form of this toxin. Despite this it
is a time-consuming and expensive assay to run and as such many alternative assays have recently been
proposed. Herein we report the development of two electrochemical assays for the detection of active
botulinum neurotoxin in a pharmaceutical sample. Gold electrodes were modiﬁed with self-assembled
monolayers of the SNARE protein SNAP-25 which is selectively cleaved by active botulinum neurotoxin
A. Cyclic voltammetry and electrochemical impedance spectroscopy were performed on the modiﬁed
working electrodes to observe changes to the layer on addition of the toxin. Both methods were able
to distinguish the difference between the presence of the active toxin and a placebo containing the excip-
ients of the pharmaceutical product. The electrochemical impedance spectroscopy assay also allowed for
detection of the active toxin at concentrations as low as 25 fg/ml, with results being obtained in under an
hour outperforming the mouse bioassay.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Botulinum neurotoxins are zinc-dependant endopeptidases
known to selectively cleave the soluble N-ethylmaleimide sensi-
tive attachment protein receptor (SNARE) group of proteins [2].
Until recently the only approved method of determining the activ-
ity of a botulinum neurotoxin sample was the mouse bioassay. This
assay involves injected mice intraperitoneally with a sample of the
toxin and observing them for symptoms of the disease such as a
wasp-waist and paralysis over 4 days [16]. The mouse bioassay is
capable of detecting 10 pg/ml of active toxin; however, it is very
lengthy, expensive and has ethical problems due to the use of live
animals [14]. In 2011 a cell-based assay developed by Allergan Inc.,
was granted approval by the FDA to replace the mouse bioassay for
the potency testing of BOTOX [10]. In brief this assay uses neuro-
nal cells on a 96 well plate to which the toxin sample is added.
After incubating with the sample the cells are lysed and ELISA per-
formed using antibodies for whole and cleaved SNAP-25. This
assay is reported to equal the sensitivity of the mouse bioassay
but is still lengthy taking 3 days to perform [4]. The major beneﬁt
of the mouse bioassay and this cell based assay is the ability to
assess the toxins full activity from cell uptake through toproteolytic activity which is vital for the pharmaceutical industry.
The development of an assay which can detect and quantify the
presence of the toxin at similar or lower limits of detection in a
shorter period of time is desirable to improve on the existing meth-
ods whilst eliminating the need for live animals. A point of care
sensor for suspected botulinum poisoning cases would not need
to assess all modes of action just the presence of toxin in a blood
sample. This study reports the development of a biosensor for
the detection of active botulinum neurotoxin A using gold elec-
trodes modiﬁed with the SNARE protein SNAP-25.
We previously reported a colourimetric assay based on a SNAP-
25 monolayer on colloidal gold [8]. This assay has been developed
into an electrochemical assay presented in this paper.
Cyclic voltammetry and electrochemical impedance spectros-
copy were employed to monitor the interaction between the active
toxin and SNAP-25 at the gold surface. A gold electrode can be eas-
ily modiﬁed with the SNAP-25 protein due to its four cysteines that
are able to form strong sulfur-gold bonds to give a monolayer on
the surface. Cleavage of nine amino acids from the SNAP-25 protein
upon incubation with botulinum neurotoxin A causes a signiﬁcant
change at the surface which is detected using these techniques.
Electrochemical techniques, such as cyclic voltammetry and
electrochemical impedance spectroscopy, are label-free techniques
that are highly sensitive to changes and interactions at a surface.
Over the past few years a number of advances have been made
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toxins, pathogens and biomarkers [3,12,17] due to their high sen-
sitivity and rapid detection times. Cyclic voltammetry provides
information on the amount of oxidisable species on a working elec-
trode and the number of electrons involved in the oxidation, which
is given in terms of charge [13]. Variations in the charge indicate
binding events and changes to the self-assembled monolayer.
Impedance is a measure of the complex resistance met when cur-
rent ﬂows through a circuit made up of resistors, capacitors and
inductors. Electrochemical impedance spectroscopy utilises redox
probes such as Fe(CN)63/4 or Ru(NH3)62+/3+ measuring the ability
of these ions to become oxidised and reduced at the working
electrode [1]. At unmodiﬁed working electrodes the route to the
electrode surface is not blocked and these chemicals easily
undergo the reactions. If the electrode surface is modiﬁed by an
alkanethiol or a protein then the ions are more blocked increasing
the charge transfer resistance (Rct) of the circuit [11].2. Materials and methods
Gold working electrodes were purchased from Winkler GmbH
Germany, SNAP-25 was from Abcam (ab155885) and all other
chemicals were purchased from Sigma Aldrich. Dysport samples
containing lyophilised Clostridium botulinum Type A toxin-haemag-
gluttinin complex (4.35 ng), human serum albumin (125 lg) and
lactose (2.5 mg) and placebos containing the excipients from Dys-
portwere kindly supplied by IPSEN Biopharm. Water was puriﬁed
and had a nominal resistivity of 18 MO cm at 25 C.
All measurements were performed using an Autolab PGSTAT 30
computer-controlled electrochemical measurement system (Eco
Chemie, Holland) with a home-made three electrode cell with a
SNAP-25 modiﬁed Au(111) working electrode, a platinum counter
electrode and a saturated calomel reference electrode.2.1. Self-assembled monolayers of SNAP-25
Gold working electrodes were ﬂame annealed to produce
Au(111) terraces [7]. After cooling they were placed in a solution
of SNAP-25 (125 lg/ml) in water and left to incubate for 48 h at
20 C.2.2. Stripping voltammetry of SNAP-25 monolayer
Gold electrodes were removed from the SNAP-25 solution,
rinsed thoroughly with ultra-pure water, dried under nitrogen
and sealed in the electrochemical cell. NaOH (100 mM, 15 ml)
was added and degassed for 20 min with nitrogen. Two cyclic vol-
tammograms were measured between 0 and 1100 mV at a scan
rate of 50 mV s1.-10
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Fig. 1. Voltammograms at a sweep rate of 50 mV s1 in 0.1 M NaOH; the working
electrodes were SNAP-25 modiﬁed Au(111) and a bare Au(111) slide.2.4. Cyclic voltammetry assay
The sample (200 ll) was added to the SNAP-25 modiﬁed gold
electrode and incubated for 10 min at 37 C. The sample was then
removed and the surfaced rinsed thoroughly with ultra-pure
water. Phosphate buffer (100 mM, pH 7) was added to the cell
and degassed for 20 min with nitrogen before the voltammogram
was performed with a start potential of 0 mV to a ﬁrst vertex
potential of 1100 mV at a scan rate of 50 mV s1. The resulting scan
was compared to an average scan of whole SNAP-25.2.5. Electrochemical impedance spectroscopy using ferri/ferrocyanide
as a redox probe
Electrochemical impedance spectroscopy (EIS) was performed
using ferri/ferrocyanide (500 lM) as a redox probe in potassium
chloride (100 mM). A potential of 147 mV was applied with a per-
turbation amplitude of 10 mV s1 between the frequencies of
25 kHz and 0.1 Hz.
The impedance of the SNAP-25 monolayer was measured as
above then the redox probe solution removed and the cell thor-
oughly rinsed with ultrapure water. Samples (200 ll) were added
to the electrode surface and incubated for 25 min at 37 C then
removed and the surface again rinsed with ultrapure water. Redox
probe was then added to the cell and the impedance re-measured.3. Results and discussion
3.1. Stripping voltammogram of SNAP-25 monolayer
Binding of the SNAP-25 monolayer was analysed using cyclic
voltammetry. Fig. 1 shows the voltammogram of a SNAP-25 mod-
iﬁed Au(111) electrode compared with a bare Au(111) electrode.
The characteristic peak for the reduction of a gold sulfur bond is
shown by Peak 1, at 970 mV. The reaction is outlined in Eq. (1)
where X represents each SNAP-25 molecule presuming all four cys-
teines bind to the electrode.
XðS AuÞ4 þ 4e ! 4Auþ XðSÞ4 ð1Þ
Peak 2, at 850 mV, indicates some of the thiols re-adsorb onto
the gold surface as the scan returns to more positive potentials as
in Eq. (2).
4Auþ XðSÞ4 ! XðS AuÞ4 þ 4e ð2Þ3.2. Cyclic voltammetry assay for detection of botulinum neurotoxin
A cyclic voltammetry assay was developed that could detect the
toxin by measuring changes to the charge of a SNAP-25 monolayer
after incubating with the toxin. A typical voltammogram is shown
in Fig. 2.
The anodic peak at 950 mV occurs on the oxidation of the gold
and protein, the charge was calculated from the area of this peak
with the expected decrease in charge on addition of the toxin as
shown.
Fig. 3 shows the correlation graph of change in charge against a
range of known concentrations of Botulinum neurotoxin in
triplicate.
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Fig. 2. Voltammogram of a typical SNAP-25 monolayer and a SNAP-25 monolayer
after incubation with 500 pg/mL of toxin.
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Fig. 3. Correlation graph for cyclic voltammetry assay. Errors calculated to ±1SD.
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Fig. 4. Nyquist plot showing a decrease in charge transfer resistance after
incubation with 75 fg/ml botulinum neurotoxin.
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Fig. 5. Graph showing percentage difference of charge transfer resistance against a
range of botulinum neurotoxin (Dysport) concentrations. Errors calculated to
±1SD.
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750 pg/ml with a good correlation over the range of 375–750 pg/
ml (r2 = 0.9627) with the difference in charge plateauing at the
upper and lower points. The placebo sample (shown in grey) pro-
duced a much higher response than the toxin samples due to the
binding of the human serum albumin to SNAP-25. The difference
in charge was calculated from an average SNAP-25 voltammogram
rather than for each individual layers as alkanethiol monolayers
due to damage caused by repetitive scanning between the poten-
tials of 500 and 800 mV [5]. This caused the large errors seen on
the correlation graph as there are slight differences between each
SNAP-25 layer.-40
Fig. 6. Graph showing the difference between responses of placebo, denatured
toxin and active toxin samples.3.3. Electrochemical impedance spectroscopy assay
Electrochemical impedance spectroscopy was employed to pro-
vide a more direct comparison between the SNAP-25 monolayer
before and after incubation with the botulinum neurotoxin. EIS is
a much less damaging technique than cyclic voltammetry due to
the lower potential employed, therefore an initial scan of the
SNAP-25 monolayer can be run before incubation with the toxin
without causing damage to the monolayer.
Fig. 4 shows a typical Nyquist plot for a SNAP-25 modiﬁed elec-
trode before and after incubation with 75 fg/ml of toxin. Data was
ﬁtted to the Randles circuit with a constant phase element with
charge transfer resistance indicated by the diameter of the semicir-
cle [15].
The plot shows the expected decrease in Rct after incubation
with botulinum neurotoxin from 146.6 O to 95.7 O indicating that
the toxin has cleaved the protein. This was repeated over a range oftoxin concentrations in triplicate which gave the correlation graph
shown in Fig. 5.
Data was presented as a percentage change in Rct to normalise
the difference between SNAP-25 monolayers. All toxin concentra-
tions showed a decrease in Rct as expected. The placebo showed
a large increase in Rct as seen previously in the cyclic voltammetry
assay indicating the binding of human serum albumin. Denatured
toxin also produced an increase in charge transfer resistance (data
not shown) showing that the proteolytic activity of the toxin was
causing the change. The data produced large errors with no corre-
lation between toxin concentration and change in Rct however
there was a clear difference between active toxin and the placebo
product as shown in Fig. 6.
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tance and toxin shows a decrease a simple yes/no response can
be used to determine the presence of toxin. This would be of use
in clinical or security settings where the concentration of the toxin
is not of great importance.
4. Conclusion
Industrial pressures have caused a demand for quicker, cheaper
assays for botulinum neurotoxin. The assays presented in the paper
are much quicker than the mouse bioassay taking hours rather
than days to perform. The impedance biosensor also outperforms
the mouse bioassay on sensitivity producing a response down to
25 pg/mL of toxin. The major beneﬁt of these assays over some oth-
ers in development, such as ELISA, is the detection of active toxin
through monitoring the proteolytic activity rather than just the
presence of the molecule. These assays also clearly distinguish
between the toxin product and the placebo sample which has pre-
viously caused problems due to the slight proteolytic activity of
HSA [9]. When performed correctly EIS does not damage the bio-
logical layer giving an advantage, allowing for direct comparison
between the individual SNAP-25 monolayers before and after
incubation with the toxin.
The lack of correlation in the EIS assay means it would not be
suitable for the pharmaceutical industry however it may be of
use in clinical or security environments where only the presence
of toxin needs to be detected. For transfer into other environments
the samples would need a small amount of processing such as
immunochromatography to ﬁlter out the toxin from other prote-
ases that may be present. Currently these assays have only been
tested on serotype A but with types C and E also cleaving SNAP-
25 the assays may be ﬂexible in detecting these other serotypes.
These assays could also be further developed to detect all serotypes
of the toxin by modifying the gold surface with the other SNARE
proteins Synaptobrevin and Syntaxin.
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